The Plasma Kallikrein–Kininogen Pathway Is Critical in the Pathogenesis of Colitis in Mice

Bo Wang1, Aizhen Yang1, Zhenzheng Zhao1, Chao He1, Yuanyuan Liu1, Robert W. Colman2, Jihong Dai2,3 and Yi Wu1,2*

1Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, 2The Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, United States, 3Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States

The kallikrein–kinin system (KKS) consists of two serine proteases, prekallikrein (pKal) and factor XII (FXII), and a cofactor, high-molecular-weight kininogen (HK). Upon activation of the KKS, HK is cleaved to release bradykinin. Although the KKS is activated in humans and animals with inflammatory bowel disease (IBD), its role in the pathogenesis of IBD has not been characterized. In the present study, we determined the role of the KKS in the pathogenesis of IBD using mice that lack proteins involved in the KKS. In two colitis models, induced by dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS), mice deficient in HK, pKal, or bradykinin receptors displayed attenuated phenotypes, including body weight loss, disease activity index, colon length shortening, histological scoring, and colonic production of cytokines. Infiltration of neutrophils and inflammatory monocytes in the colonic lamina propria was reduced in HK-deficient mice. Reconstitution of HK-deficient mice through intravenous injection of HK recovered their susceptibility to DSS-induced colitis, increased IL-1β levels in the colon tissue and bradykinin concentrations in plasma. In contrast to the phenotypes of other mice lacking other proteins involved in the KKS, mice lacking FXII had comparable colonic inflammation to that observed in wild-type mice. The concentration of bradykinin was significantly increased in the plasma of wild-type mice after DSS-induced colitis. In vitro analysis revealed that DSS-induced pKal activation, HK cleavage, and bradykinin plasma release were prevented by the absence of pKal or the inhibition of Kal. Unlike DSS, TNBS-induced colitis did not trigger HK cleavage. Collectively, our data strongly suggest that Kal, acting independently of FXII, contributes to experimental colitis by promoting bradykinin release from HK.

Keywords: kallikrein–kinin system, colitis, inflammation, neutrophil, cytokine

INTRODUCTION

Inflammatory bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn's disease (CD), are debilitating disorders caused by gastrointestinal mucosal damage and inflammation. The etiology and pathogenesis of IBDs remain unknown; however, they are likely triggered through a complex interplay between genetic susceptibility, host immune system dysregulation, and environmental factors.
factors (1). In general, IBDs are associated with a compromised gastrointestinal barrier, leading to inflammation directly through tissue injury and indirectly via the production of various pro-inflammatory mediators that recruit immune cells. Plasma proteolytic cascades have been also reported to be important in IBD development (2).

The plasma kallikrein–kinin system (KKS) consists of a group of plasma proteins that respond to pathophysiological stimuli and tissue injury (3), specifically two serine proteinases [coagulation factor XII (FXII) and prekallikrein (pKal)], and a non-enzymatic cofactor [high-molecular-weight kininogen (HK)] (4). KKS proteins interact with many physiologic and pathophysiologic systems, such as the immune and complement systems (3). The KKS cascade is activated when FXII and HK assembled on negatively charged surfaces. Following autocalyysis, FXIIa cleaves pKal, generating Kal, which in turn activates additional FXII zymogens. Activated Kal, which is the major bradykinin-releasing enzyme in blood, cleaves HK to HKa and additional FXII zymogens. Activated pKal can also be activated by the lysosomal enzyme prolylcarboxypeptidase and heat-shock protein 90 independently of FXII (6–9). Bradykinin can be hydrolyzed by carboxypeptidase N (in plasma) or carboxypeptidase M (on endothelial cells) to produce des(Arg9)-bradykinin. Bradykinin and des(Arg9)-bradykinin are the agonists of two G protein-coupled receptors (designated as B2R and B1R, respectively) (10, 11).

Activation of the KKS has been documented in patients with active UC and CD (12, 13) and in rat models of acute colitis (14, 15). A significant decrease in pKal and HK levels was observed in plasma of patients with active UC (12, 13), presumably reflecting increased KKS activation/consumption. Kal immunoreactivity was stronger in the intestines of patients with UC and CD than in those of normal controls, suggesting that pKal might activate the KKS extravascularly following extravasation/diffusion of plasma through injured intestinal tissues (13). B1R and B2R are expressed in the intestines of healthy individuals and patients with UC and CD, but their expression levels are significantly increased in active UC and CD intestines (16). In a genetically susceptible strain of Lewis rats with granulomatous enterocolitis induced by peptidoglycan–polysaccharide polymers from group A streptococci, consumption of pKal and HK proteins was closely correlated with chronic intestinal inflammation (17, 18). In a distinct indomethacin-induced enterocolitis model, Lewis rats also displayed KKS activation (19), and in the human leukocyte antigen-B27 transgenic rat model of human IBD, a monoclonal antibody against HK decreased clinical scores and colonic lesions of pre-existing IBD (20). Another disease model, in which IBD was induced in Sprague-Dawley rats by dextran sulfate sodium (DSS), demonstrated that the B2R antagonist FR173657 inhibited shortening of the colon, suggesting that KKS activation worsens colitis due to bradykinin-induced B2R signaling (21).

Although these observations in humans and rats suggest that KKS activation can aggravate the pathology of IBD, the respective roles of pKal, FXII, HK, and kinin-signaling pathways have not been systematically characterized. In the present study, this issue was addressed using two models of experimental colitis, induced by DSS or 2,4,6-trinitrobenzene sulfonic acid (TNBS), in transgenic mouse strains lacking HK, pKal, FXII, or B2R/B1R. Our results link the pathological outcome of DSS or TNBS-induced colitis to kinin release via the pKal/HK pathway. Intriguingly, FXII-deficient mice remained susceptible to colitis, suggesting that activation of the KKS in the inflamed mucosa occurs through a pathway independent of this factor and contact system-induced coagulation.

**MATERIALS AND METHODS**

**Mice**

Klkb1<sup>−/−</sup> mice with a disrupted pKal gene were generated by transcription activator-like effector nucleases (TALEN)-mediated targeted gene disruption, with the assistance of Cyagen Bioscience, Inc. (Santa Clara, CA, USA). The constructed TALEN repeats were designed to bind to exon 4 of the Klkb1 gene and were subcloned into a mammalian expression vector, pCMV-TALEN. Poly A-tailed mRNAs were produced using the Ambion mMessage mMachine kit for microinjection (Foster City, CA, USA). In vitro-transcribed mRNA encoding this TALEN pair was microinjected into fertilized eggs from C57BL/6 mice. Approximately 30 injected zygotes were transferred into the fallopian tubes of each recipient mouse. A 25-base deletion (GAGCATTCCAGGACTTTGCCAAGA; 243–267 of the open reading frame) at exon 4 was detected in the C57BL/6 background of the resulting offspring, which were selected for further breeding and characterization. This 25-base deletion caused a frameshift and created an early stop codon, resulting in truncated Klkb1 (pKal) after Leu92. Offspring were identified by genotyping via tail-biopsied DNA using the following primers in a 35-cycle PCR reaction: P1: 5′-GCATTACAGGACTTTGCC-3′; P2: 5′-TCTTTCCTGGTGTCCTGC-3′; P3: 5′-GGTGTCCTCAAGAAT-3′; P4: 5′-GGCTGAGCATAACTACG-3′. These primer pairs were designed to yield PCR products derived from the wild-type and 25 bp-deleted alleles. RNA was extracted from the mouse liver using TRIzol (Invitrogen, Carlsbad, CA, USA). Total RNA (2 μg) was used for first-strand cDNA synthesis using oligo(dT)<sub>12</sub> and Superscript II RNase H<sub>−</sub> Transcriptase (Invitrogen). The product of the first-strand reaction was amplified by PCR using primers P1 (indicated above); P5: 5′-GGTTGTTCCGCCTTGACT-3′; and β-actin (F: 5′-GTCCCTCACCCTGCACGGAGGAG-3′; R: 5′-GCTGCCTCAACCTCAACCC-3′), to ensure that equal amounts of cDNA were added to each reaction. Products were analyzed on 2% agarose gels. To verify the absence of the pKal protein, plasma from wild-type and Klkb1<sup>−/−</sup> mice was analyzed by immunoblotting with a goat polyclonal anti-pKal antibody (R&D Systems, Minneapolis, MN, USA) and a secondary donkey anti-goat antibody conjugated with DyLight 800 (Li-Cor, Lincoln, Nebraska, USA), Homozygous Klkb1<sup>−/−</sup> mice were viable, healthy, fertile, born with normal Mendelian frequency and did not display any gross physical or behavioral abnormalities.

Mice lacking HK (Kng1<sup>−/−</sup>) were generated in our previous studies (22). Double knockout mice lacking both bradykinin receptors (B1RB2R<sup>−/−</sup>) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Mice lacking Factor XII (FXII<sup>−/−</sup>) were...
kindly provided by Dr. F. Castellino from the University of Notre Dame. All knockout mice, including Kng1-/- and Klkb1-/- mice, were backcrossed on a C57BL/6 background for more than 10 generations. Mice were maintained in a pathogen-free facility and monitored in accordance with the guidelines of the Institutional Animal Care and Use Committee.

**Figure 1** | Kng1 deficiency ameliorates dextran sulfate sodium (DSS)-induced colitis. (A,B) WT C57BL/6 mice were treated with distilled water (DW) or 2.5% DSS for 8 days. Bradykinin levels (A) and APTT (B) were measured in the plasma. (C–E) Four groups of Kng1+/+ mice and Kng1-/- mice (n = 12) were treated with DW or 2.5% DSS for 8 days. Body weight change (C) and disease activity index (D) were monitored daily. Body weight change was compared with body weight on day 0. On day 8, the cecum and colon were collected. The representative gross appearance of the colon is shown here [left panel, (E)]. Colon length was measured [right panel, (E)].

(F) The distal colon was processed for histological H&E staining. Representative images (left panel) and histological scoring (right panel) are shown. Statistical significance was determined using Student’s t-test (A,F), one-way analysis of variance (C,E) or Mann–Whitney test (B,D): *P < 0.05; **P < 0.01; ***P < 0.001.
**Induction and Assessment of DSS-Induced Colitis**

Mice used for the induction of colitis with DSS and TNBS were gender- and age-matched, with 8-week-old littermates of both genders in a ratio of 1:1. Treatment and data acquisition, including scoring, were performed in a blinded manner. For DSS-induced colitis, mice were treated with 2.5% (wt/vol) DSS (molecular mass = 36–50 kDa; MP Biomedicals, Santa Ana, CA, USA) in drinking distilled water (DW) ad libitum for 8 days with DW alone for the control group (23). The amount of DSS consumed by each mouse was recorded. There were no differences in intake between experimental groups. Mice were weighed every day to determine percentage weight changes, which was calculated as percentage body weight change (weight at day x/weight at

**FIGURE 2** Kng1 deficiency reduces cytokine production and recruitment of neutrophil and inflammatory monocytes to inflamed colonic tissue. Four groups of Kng1+/+ mice and Kng1−/− mice (n = 12) were treated with distilled water (DW) or 2.5% dextran sulfate sodium (DSS) for 8 days. (A) Cytokine levels in the colon homogenates were measured by enzyme-linked immunosorbent assay (ELISA). (B) RNA was isolated from the colon and cytokine expression levels were measured by real-time RT-PCR. (C) Myeloperoxidase (MPO) concentrations were measured in colon homogenates using ELISA. (D) Lamina propria cells were isolated from the colon, and the percentage of CD45+CD11b+Gr-1+ cells was assessed by flow cytometry. Statistical significance was determined by one way analysis of variance. *P < 0.05; **P < 0.01; ***P < 0.001.

**FIGURE 3** Reconstitution of Kng1−/− mice with high-molecular-weight kininogen (HK) recovers their susceptibility to dextran sulfate sodium (DSS)-induced colitis. Three groups of Kng1+/+, Kng1−/−, and Kng1−/− mice replenished with HK were treated with 2.5% dextran sulfate sodium (n = 4). On day 0, Kng1−/− mice were injected with HK (330 μg/mouse) through the tail vein 30 min before treatment with 2.5% DSS, followed by their daily injection of HK at the same dose. Body weight change (A) and disease activity index (B) were monitored every day. The data of DAI on day 7 are shown. In (A), day 6, Kng1+/+ vs. Kng1−/−: P < 0.01, Kng1+/+ + HK vs. Kng1−/−: P < 0.05; day 7, Kng1+/+ vs. Kng1−/−: P < 0.001, Kng1+/+ + HK vs. Kng1−/−: P < 0.01. On day 7, the mice were sacrificed and the cecum and colon were collected. The representative gross colon appearance is shown [left panel, (C)], and colon length was measured [right panel, (C)]. IL-1β levels in the colon homogenates (D) and bradykinin concentrations in plasma (E) were measured by enzyme-linked immunosorbent assay. Statistical significance was determined by one-way analysis of variance. *P < 0.05; **P < 0.01.
day 0 × 100). The animals were monitored clinically for rectal bleeding, diarrhea, and other general health signs, including hunched posture and failure to groom. The disease activity index (DAI) was assessed by the combined score of weight loss, stool consistency, and bleeding. Scores were defined as follows: stool consistency was graded 0 for no diarrhea, 2 for loose stool that did not stick to the anus, and 4 for liquid stool that stuck to the anus. The presence of fecal blood was graded 0 for none, 2 for moderate, and 4 for gross bleeding. For weight loss evaluation, a value of 0 was assigned if the body weight remained within 1% or higher of baseline, 1 for a 1–5% loss, 2 for a 5–10% loss, 3 for a 10–15% loss, and 4 for greater than 15% loss. For histological observations, the colons were isolated, flushed with PBS, and fixed in 4% formaldehyde solution. Tissues were embedded in paraffin, sectioned, mounted on glass slides, and deparaffinized. H&E-stained paraffin section images were acquired, followed by pathological evaluation in a blinded manner and scored as described previously (24). Briefly, the severity of inflammation (0–3: none, slight, moderate, severe); depth of injury (0–3: none, mucosal, mucosal and submucosal, transmural); and crypt damage (0–4: none, basal 1/3 damaged, basal 2/3 damaged, only surface epithelium intact, entire crypt, and epithelium loss) were monitored. The score of each parameter was multiplied by a factor reflecting the percentage of tissue involvement (1–4: 0–25, 26–50, 51–75, and 76–100%, respectively) and summed. White blood cell count and partial thromboplastin time (APTT) were measured as previously described (25).

**Induction and Assessment of TNBS-Induced Colitis**

According to a previously described methodology (23), 5% TNBS (Sigma-Aldrich, St. Louis, MO, USA) solution mixed 1:1 (v/v)
with absolute ethanol (EtOH) was applied intrarectally to mice. Control mice received 50% EtOH. Histological scoring was based on a semiquantitative scoring system where features were graded as follows: extent of destruction of normal mucosal architecture (0: normal; 1, 2, and 3: mild, moderate, and extensive damage, respectively); presence and degree of cellular infiltration (0: normal; 1, 2, and 3: mild, moderate, and transmural infiltration, respectively); extent of muscle thickening (0: normal; 1, 2, and 3: mild, moderate, and extensive thickening, respectively); presence or absence of crypt abscesses (0: absent; 1: present); and presence or absence of goblet cell depletion (0: absent; 1: present). The scores for each feature were summed, with a maximum possible score of 11.

**Isolation of Colon Lamina Propria (LP) Cells and Flow Cytometric Analysis**

Intestinal LP cells were obtained following digestion of the colon in RPMI containing 5% fetal calf serum, 5 mM EDTA, and 2 mM dithiothreitol (26). Briefly, the colons were minced, the pieces were incubated with agitation in digestion buffer for 30 min and filtered. The retained fraction was digested in RPMI containing 5% fetal calf serum, 400 U/mL of type-I collagenase (Thermo Scientific, Waltham, MA, USA), and 0.1 mg/mL of DNase I (Takara Bio, Inc., Shiga, Japan) and filtered. The flow-through was centrifuged, and the cells were stained using FITC-conjugated anti-CD45, PE-conjugated anti-CD11b, and PerCP-conjugated Gr-1 (eBioscience, San Diego, CA, USA) (27), for flow cytometric analysis.

**Enzyme-Linked Immunosorbent Assay (ELISA)**

Part of each colon was homogenized mechanically in PBS containing 1% NP-40 and complete protease inhibitor cocktail containing AEBSEF, Aprotinin, Bestatin, E-64, Leupeptin, and Pepstatin A (I3786, Sigma-Aldrich). Mouse cytokines (R&D Systems) and myeloperoxidase (MPO) (USCN Life Science, Wuhan, China) were measured by ELISA. Plasma bradykinin concentrations were determined using an ELISA kit (Enzo Life Science, Farmingdale, NY, USA).

**Chromogenic Assay of Kal and FXIIa Activity**

Kal activity was spectrophotometrically monitored via conversion of the chromogenic substrate H-D-Pro–Phe–Arg-pNA·2HCl, S-2302 (0.5 mM; HYPHEN BioMed, Neuville-sur-Oise, France) using a Bio-Kinetics Reader (BioTek Instruments, Inc., Winooski, VT, USA), as described previously (28, 29). To determine the specific effect of DSS on the activation of Kal, a monoclonal antibody (IgG1) against Kal M0202-H03 (Dyax, now a part of Shire, Burlington, MA, USA) was used, and an isotype-matched IgG1 (Sigma) was used as a control. Human and mouse plasma was prepared using sodium citrate as coagulant. In brief, 90 µL of diluted plasma (1:1) was preincubated with 10 µL of antibody or control buffer for 30 min. Ninety microliters of pretreated plasma were incubated with 10 µL of DSS for 10 min. Ten microliters of DSS-treated plasma were added to 90 µL of substrate in 96-well plate. A chromogenic substrate of FXIIa (SPECTROZYME®, Sekisui Diagnostics, Lexington, MA, USA) was used to measure FXIIa generation. The high sensitivity and specificity for FXIIa was demonstrated in a previous study (30). The positive control for FXII activation was 100 µg/mL of kaolin. The optical density of 0.5 mM substrate hydrolysis was measured at 405 nm using a spectrophotometer (SpectraMax M5, Molecular Devices, Sunnyvale, CA, USA) (31).
Western Blotting
To identify activated/cleaved components of the KKS, platelet-free human and mouse plasma were prepared using EDTA as an anticoagulant. After centrifugation at 1,000 × g for 10 min, plasma was collected and incubated with DSS for 30 min, before the addition of Laemmli loading buffer containing 2-mercaptoethanol to stop the reactions. Cleavage of the KKS proteins was analyzed by immunoblotting using a rabbit polyclonal anti-HK antibody (Abgent, Inc., San Diego, CA, USA) which can detect the heavy chain of both human and mouse HK, a rabbit monoclonal anti-pKal antibody for recognizing human pKal (Abcam, Cambridge, MA, USA), a goat polyclonal anti-pKal antibody for recognizing mouse pKal (R&D Systems, Minneapolis, MN, USA) and a monoclonal anti-FXII antibody for recognizing human FXII (B7C9, ThermoFisher Scientific, Waltham, MA, USA).

Real-time RT-PCR and PCR
Total RNA was extracted using TRizol (Invitrogen). cDNA was synthesized with the RevertAid First-Strand cDNA Synthesis Kit (Thermo Scientific). Quantitative real-time PCR was performed using the Maxima SYBR Green/ROX qPCR Master Mix kit (Fermentas, Vilnius, LT, USA) according to the manufacturer’s instructions. mRNA levels were normalized to the levels of β-actin. Primer pairs used are as follows: interleukin-1β (IL-1β) F: 5′-TGTTCTTTCCGCTGACCT-3′, R: 5′-CAGC
TCATATGGTCCGACA-3', IL-6 F: 5'-GGTGACAACCCAGGCCTTCCC-3', R: 5'-AAGGCTCGACCTGTGAAATGCGT-3'; interferon-γ F: 5'-GGGTTAGACAAAGGCTTAT-3', R: 5'-TC TTTACATGACGGCAGTTT-3'; tumor necrosis factor (TNF)-α F: 5'-GGGTTAGACAAAGGCTTAT-3', R: 5'-CTGATGAGGGAGGCCATCT-3', β-actin F: 5'-GTTGATGTTGCTCTAGAC TTGAC-3', R: 5'-ATGCCACAGGAGTCCATACC-3'.

**Statistical Analysis**

GraphPad Prism software was used for statistical evaluation (GraphPad, Inc., Chicago, IL, USA). The data were expressed as the mean ± SEM of at least three independent experiments, unless otherwise indicated. For parametric comparison, one-way analysis of variance (ANOVA) followed by Tukey's test for multiple groups, or a two-tailed, unpaired Student's t-test for two groups were used. For nonparametric comparison, a Mann–Whitney test was used. A P < 0.05 was considered statistically significant.

**RESULTS**

*Kng1*−/− Mice Are Protected against DSS-Induced Colitis

The DSS-induced colitis model is often used in IBD research because of its rapidity, simplicity, reproducibility, and controllability. In DSS-treated WT mice, bradykinin levels and APTT, an index of intrinsic coagulation activity, were significantly increased compared to control mice treated with DW (Figures 1A, B), suggesting activation of the KKS and release of bradykinin in this model. To determine the role of HK in DSS-induced colitis, we generated a mouse strain with a disrupted gene for *Kng1*, which encodes HK. On day 8 after DSS administration, control *Kng1*+/+ mice developed severe colitis, with symptoms including body weight loss, loose stool consistency, and gross bleeding, as demonstrated by the DAI compared to that of DW-treated mice (Figures 1C, D). DSS-treated *Kng1*+/+ mice also had a significantly shortened colons (Figure 1E). Histological analysis of the colons from *Kng1*+/+ mice revealed loss of epithelial integrity and crypts, submucosal edema, and intense infiltration of inflammatory cells, as well as a remarkable increase in the histological score (Figure 1F). In contrast, DSS-treated *Kng1*−/− mice had significant amelioration of colitis development and severity, as indicated by body weight, DAI, colon length, and histological changes (Figures 1C–F), suggesting that HK is required for the pathogenesis of DSS-induced colitis.

Genetic studies have shown that inflammatory cytokines, such as TNFα, IL-1β, IL-6, and IFN-γ, are elevated in colitis, and are important in the development of mucosal inflammation (32–35). We, therefore, determined if HK regulates the production of these cytokines. On day 8 after DSS treatment, the concentration of TNFα, IFN-γ, IL-1β, and IL-6 were significantly increased in the colon homogenate of DSS-treated WT mice compared to in DW-treated WT mice (Figure 2A). In contrast, these cytokine levels were significantly lower in DSS-treated *Kng1*−/− mice than in WT mice (Figure 2A). Moreover, the mRNA levels of TNFα, IFN-γ, IL-1β, and IL-6 were upregulated in DSS-treated WT mice and significantly downregulated in DSS-treated *Kng1*−/− mice (Figure 2B). These observations suggest that HK is involved in cytokine production in DSS-induced colitis.

Infiltration of neutrophils into the intestinal mucosa is a pathological hallmark of active IBD, which contributes to tissue damage. Abundant infiltrated neutrophils have been detected in the colon LP and epithelial layer of human patients with IBD, and in experimental mouse colitis models (36, 37). Since MPO is abundantly expressed in neutrophils, we measured MPO concentration in the colon homogenate to represent neutrophil recruitment (38, 39). DSS treatment significantly increased MPO levels in WT mice (Figure 2C); however, the MPO level in DSS-treated *Kng1*−/− mice was significantly lower than in WT mice (Figure 2C). To quantify the recruitment of neutrophils and inflammatory monocytes, LP cells were

**FIGURE 7 | Generation and characterization of Klkb1−/− mice. (A)** Schematic design of the mouse Klkb1 gene deletion. Exon 4 of Klkb1 gene was selected as the transcription activator-like effector nucleasess target site. PCR primer (P1, P2, P3, P4, and P5) positions are shown. Sequencing confirmed the deletion of 25 bp (GAGCATTACAGGGACCTTGGCAAGA; 243–267 of the ORF) in the knockout allele. (B) PCR of the genomic DNA yielded a 200-bp product for the WT allele using primer pairs P1 and P2, and a 308-bp product for the knockout allele using primer pairs P3 and P4. (C) Expression of Klkb1 mRNA in the liver. Total RNA was isolated from the liver of WT mice and Klkb1−/− mice. The expression of Klkb1 mRNA was measured by RT-PCR using primer pairs P1 and P5. β-Actin mRNA served as a loading control. (D) Expression of prekallikrein (pKal) antigen in the plasma was determined by immunoblotting with an anti-pKal antibody with histidine-rich glycoprotein as a loading control.
analyzed by flow cytometry. Neutrophils and inflammatory monocytes, defined as CD11b+Gr-1hi cells (Figure 2D, left panel) were significantly increased in DSS-treated WT mice, while the number of these cells was reduced in DSS-treated 

\[ \text{Kng1}^{−/−} \] mice (Figure 2D, right panel). These results indicate that in the absence of HK, the infiltration of inflammatory cells into the gut mucosa decreases.

Finally, we tested whether the reconstitution of 

\[ \text{Kng1}^{−/−} \] mice with HK recovers their susceptibility to DSS-induced colitis. Unlike 

\[ \text{Kng1}^{−/−} \] mice, 

\[ \text{Kng1}^{−/−} \] mice replenished with HK had severe body weight loss and DAI comparable to wild-type mice (Figures 3A,B). Reconstitution of 

\[ \text{Kng1}^{−/−} \] mice with HK also resulted in shortened colon length (Figure 3C), increased IL-1β levels in the colon tissue, and increased bradykinin concentration in the plasma (Figures 3D,E). These results indicate that systemic administration of exogenous HK in 

\[ \text{Kng1}^{−/−} \] mice rescues the susceptible phenotype in the DSS model, suggesting that the phenotype of 

\[ \text{Kng1}^{−/−} \] mice results from the loss of HK.

**Combined Deficiency of Two Bradykinin Receptors (B1R and B2R) Attenuates DSS-Induced Colitis and Suppresses Colonic Cytokine Production and MPO Levels**

Upon activation of the KKS, HK is cleaved to release bradykinin. Because HK deficiency inhibited DSS-induced colonic inflammation (Figures 1 and 2), we determined the role of the bradykinin

---

**FIGURE 8** | Prekallikrein deficiency attenuates dextran sulfate sodium (DSS)-induced colitis. Four groups of 

\[ \text{Kkb1}^{+/+} \] mice and 

\[ \text{Kkb1}^{+/−} \] mice were treated with distilled water (DW) or 2.5% DSS for 8 days (n = 12). Body weight change (A) and disease activity index (B) were monitored every day. (C) On day 8, the cecum and colon were isolated. Representative gross appearance of the colons (left) is shown. Colon length (right) was measured. (D) Representative H&E staining (left panel) is shown. Histological scoring was calculated (right panel). Statistical significance was determined by one-way analysis of variance (A,C,D) and Mann–Whitney test (B): *P < 0.05; **P < 0.01; ***P < 0.001.
receptors in mice lacking both B1 and B2 bradykinin receptors (B1R/B2R<sup>−/−</sup>). Although B1R/B2R<sup>−/+</sup> mice displayed severe colitis over the 8 days of DSS treatment, B1R/B2R<sup>−/−</sup> mice had a delayed onset and a noticeably milder course of disease, as evidenced by their significantly lower body weight loss and DAI (Figures 4A,B). While B1R/B2R<sup>−/+</sup> mice experienced significant colonic shortening and severe destructive colitis, these changes were significantly attenuated in B1R/B2R<sup>−/−</sup> mice (Figures 4C,D). Consistently, IFN-γ, TNFα, IL-1β, and IL-6 protein and mRNA levels in the colon homogenate were markedly increased in DSS-treated B1R/B2R<sup>−/+</sup> mice, whereas they were significantly downregulated in B1R/B2R<sup>−/−</sup> mice (Figures 5A,B). In addition, DSS treatment increased MPO levels in colon homogenates from B1R/B2R<sup>−/+</sup> mice, the levels were markedly reduced in B1R/B2R<sup>−/−</sup> mice (Figure 5C). These results suggest that bradykinin generated from HK is important for the pathogenesis of DSS-induced colitis.

**pKal but Not FXII Is Required for DSS-Induced Colitis**

The above observations suggested that KKS activation is involved in DSS-induced colitis. We, therefore, tested whether FXII and/or pKal are upstream of HK. First, we examined the phenotype of FXII<sup>−/−</sup> mice. In contrast to the protective phenotypes of Kng1<sup>−/−</sup> and B1R/B2R<sup>−/−</sup> mice, the weight loss (Figure 6A), DAI scores (Figure 6B), colon shortening (Figure 6C), and histological changes (Figure 6D) in FXII<sup>−/−</sup> mice were comparable to those of WT mice, indicating that FXII is not involved in the pathogenesis of DSS-induced colitis.

To determine the role of pKal in DSS-induced colitis, we generated a mouse strain with a disrupted Klkb1 gene, which encodes pKal (Klkb1<sup>−/−</sup> mice). Exon 4 of the mouse Klkb1 gene was selected as the TALEN targeting site (Figure 7A). Genotyping (Figure 7B) and sequencing results (data not shown) confirmed a 25-bp deletion (GAGCATTACAGGGACTTTGCCAAGA; 243–267 of the open reading frame) in the targeted allele. Klkb1 mRNA expression was absent in the Klkb1<sup>−/−</sup> mouse livers (Figure 7C). Moreover, the pKal antigen was not detected in the Klkb1<sup>−/−</sup> mouse plasma (Figure 7D).

After treatment with DSS, Klkb1<sup>−/−</sup> mice showed a significant decrease in body weight loss and DAI (Figures 8A,B), and exhibited significant attenuation in colon shortening and destructive colitis (Figures 8C,D) compared to Klkb1<sup>−/+</sup> mice. Cytokine concentrations were evaluated in DSS-treated Klkb1<sup>−/+</sup> mice and Klkb1<sup>−/−</sup> mice. The protein levels of major cytokines, including TNFα, IL-6, IL-1β, and IFN-γ, were significantly increased in the colon homogenates of DSS-treated Klkb1<sup>−/+</sup> mice compared to those in DW-treated mice; however, these cytokine levels significantly decreased in DSS-treated Klkb1<sup>−/−</sup> mice (Figure 9A). The mRNA levels of these cytokines in colon homogenates also significantly decreased in DSS-treated Klkb1<sup>−/−</sup> mice compared to those in Klkb1<sup>−/+</sup> mice (Figure 9B). Additionally, MPO levels were lower in the colon tissue of DSS-treated Klkb1<sup>−/−</sup> mice than in Klkb1<sup>−/+</sup> mice (Figure 9C). Bradykinin concentration also significantly decreased in DSS-treated Klkb1<sup>−/+</sup> mice compared to those in DSS-treated Klkb1<sup>−/−</sup> mice (Figure 9D). These results suggest that pKal is important in the pathogenesis of DSS-induced colitis and is responsible for the production of bradykinin.

**FIGURE 9** Prekallikrein deficiency decreases the production of cytokines and bradykinin. Four groups of Klkb1<sup>−/+</sup> mice and Klkb1<sup>−/−</sup> mice were treated with distilled water (DW) or 2.5% dextran sulfate sodium (DSS) for 8 days (n = 12). (A) Cytokine concentrations in colon homogenates were measured by enzyme-linked immunosorbent assay (ELISA). (B) RNA was isolated from the colons, and the cytokine mRNA expression was measured by real-time RT-PCR. (C) Myeloperoxidase (MPO) concentrations in colon homogenates were measured by ELISA. (D) Bradykinin concentration in the plasma was measured by ELISA. Statistical significance was determined using one-way analysis of variance: *P < 0.05; **P < 0.01; ***P < 0.001.
Inhibition of Kal Activity Ameliorates DSS-Induced Colitis

To examine whether Kal activity is involved in DSS-induced colitis, WT C57BL/6 mice were treated with a highly specific active site-blocking antibody (M202-H03) to inhibit Kal in vivo (40). M202-H03 treatment significantly inhibited DSS-induced colitis, while treatment with an isotype-matched control IgG had little effect (Figures 10A,B). Moreover, M202-H03 treatment significantly decreased plasma bradykinin levels (Figure 10C). Compared with isotype-matched control IgG, M202-H03 significantly increased the colon length (Figure 10D), ameliorated the loss of epithelial integrity and infiltration of inflammatory cells,
and decreased the histological score (Figure 10E). These data suggest that Kal activity is important in the pathogenesis of DSS-induced colitis and support a functional connection between pKal, HK and bradykinin.

**Kal Is Required for Increased Generation of Bradykinin in the Plasma of DSS-Treated Mice**

To understand the protective phenotypes observed in Kng1−/−, Klkb1−/−, and B1RB2R−/− mice in DSS-induced colitis, we measured bradykinin levels in the plasma which was prepared using EDTA as an anticoagulant. WT and B1RB2R−/− mice had a significant increase in bradykinin levels on day 8 after DSS treatment indicating activation of the KKS (Figure 11A). In contrast, DSS treatment did not yield bradykinin production in plasma of Kng1−/− mice (Figure 11A). Klkb1−/− mice had significantly lower levels of bradykinin than WT mice (Figure 11A), suggesting that pKal is required for DSS-induced bradykinin production. Consistent with the observed increase in bradykinin levels, WT and B1RB2R−/− mice also showed significantly prolonged APTT upon DSS treatment (Figure 11B). As expected, prolonged APTT was detected in both Kng1−/− and Klkb1−/− mice, with or without DSS treatment (Figure 11B). We measured FXIIa activity in these mice and found no increase in FXIIa activity in the plasma (Figure 11C), suggesting that FXII activation was not detectable in this disease model. Furthermore, we found that peripheral white blood cell numbers were comparable among these mice (Figure 11D), suggesting that at late stage colitis, the KKS does not modulate circulating inflammatory cell numbers (Figure 2D).

**DSS Activates pKal to Induce Cleavage of HK and Release Bradykinin**

To understand the mechanism by which the KKS contributes to DSS-induced colitis, we examined whether DSS induced HK cleavage as a function of concentration and time. According to immunoblotting, 100 µg/mL DSS induced complete HK cleavage in human plasma (Figure 12A). Consistently, DSS increased bradykinin production by more than 100-fold compared to PBS (Figure 12B). Activation of serine proteases like pKal depends on cleavage. We found that DSS induced cleavage of both pKal and HK in plasma as early as 2 min after incubation, without inducing FXII cleavage (Figure 12C). To determine whether DSS induced HK cleavage via pKal, we compared DSS-induced HK cleavage in the presence and absence of pKal. DSS induced the cleavage of HK in Klkb1−/− mouse plasma, but not in Klkb1−/− mouse plasma (Figure 12D), demonstrating that pKal is required for DSS-induced HK cleavage. Furthermore, we determined that HK cleavage by DSS is dependent on the activation of Kal using a specific anti-Kal antibody, M202-H03 (Ki < 1 nM) (40). In our previous study, we found that the anti-Kal antibody significantly inhibited Kal activation in rodents (29). In the present study, we used a chromogenic assay to demonstrate that DSS induced the activation of pKal, and that this induction was prevented by the anti-Kal antibody, but not its isotype-matched control IgG1 (Figure 12E). Moreover, DSS-induced HK cleavage in the plasma was completely blocked by the anti-Kal antibody (Figure 12F). These data suggest that activated pKal cleaves HK to release bradykinin, implicating this pathway in the pathogenesis of DSS-induced colitis. HK preferentially binds to negatively charged molecules in a complex with pKal. Since DSS is a negatively charged polymer of glucose with engrafted sulfate groups, it could be associated with HK, which may account for the assembly of the HK–pKal complex with DSS polymers, and subsequent activation of pKal.
FIGURE 12 | Continued
The Kallikrein–Kininogen Pathway in Colitis

Wang et al.

**Figure 12** Dextran sulfate sodium (DSS) induces activation of the kalikrein-kinin system (KKS). (A) DSS-initiated high-molecular-weight kininogen (HK) cleavage in the plasma. Human platelet-free plasma was incubated with DSS at the indicated concentrations for 30 min at 37°C. Cleavage of HK was detected using immunoblotting. (B) Human plasma was incubated with PBS (control) and 100 µg/mL of DSS at 37°C for 30 min. The production of bradykinin was measured via enzyme-linked immunosorbent assay. (C) Time course of DSS-triggered KKS activation in the plasma. Human plasma was incubated with 100 µg/mL of DSS for the indicated times. Proteins were separated by reducing SDS-PAGE and detected via immunoblotting using antibodies for HK (upper panel), prekallikrein (pKal) (middle panel), and factor XII (FXII) (lower panel). (D) Plasma from Kkbp1+/+ mice and Kkbp1−/− mice was incubated with DSS at the indicated concentrations for 30 min. Cleavage of HK was detected by immunoblotting using a polyclonal anti-HK antibody. (E) Human plasma was incubated in a total volume of 100 µL with PBS, 100 µg/mL of DSS, 100 µg/mL of DSS plus 30 µg/mL of anti-Kal antibody M202-H03, or 100 µg/mL of DSS plus 30 µg/mL of isotype-matched IgG1. Buffer plus 100 µg/mL of DSS was used as a control. Cleavage of the chromogenic substrate S-2302 indicated Kal activity, and was measured by reading the absorbance at 405 nm for 60 min. (F) Human plasma was incubated with or without 100 µg/mL of DSS in the presence of 30 µg/mL of anti-Kal antibody, or its isotype-matched control IgG1. Cleavage of HK was detected by immunoblotting using a polyclonal anti-HK antibody. (G) Human plasma was incubated with DSS or TNBS at the indicated concentrations at 37°C for 30 min. Cleavage of HK was detected by immunoblotting using a polyclonal anti-HK antibody. The above experiments were repeated three times and representative images of the blots are shown here.

**The pKal-HK Pathway Is also Important in the Pathogenesis of TNBS-Induced Colitis**

Because DSS activates the KKS, we evaluated whether the role of KKS in colitis is a model-dependent event. Similarly to DSS, TNBS can induce colitis in mice. However, unlike DSS, TNBS did not induce HK cleavage, even at a concentration of 10,000 µg/mL (Figure 12G), indicating that TNBS does not activate the KKS. Similar to our DSS model, we investigated the phenotypes of mice lacking KKS components in TNBS-induced colitis. Klngt−/− mice (Figures 13A–C), B1RB2R−/− mice (Figures 13D–F), or Kkkb1−/− mice (Figures 14A–C) had significant protection against TNBS-induced colitis, as evidenced by the amelioration of body weight loss, colon length shortening, and histological changes. However, similar to the phenotype observed in DSS-induced colitis, FXII−/− mice developed disease-like FXII+/− mice in the TNBS model (Figures 14D–F). These data support the important role of the pKal-HK pathway in the general mechanism of colitis.

**Discussion**

This is the first comprehensive genetic analysis of the role of KKS in IBD. Using KKS-knockout mice in two experimental colitis models, the present study demonstrates that pKal, HK, or combined B1R/B2R, but not FXII, deficiency protects against colitis. The study provides the first genetic confirmation of the critical importance of pKal-HK pathway in the pathogenesis of colitis in these models. The role for HK in colitis development is likely dependent on bradykinin production, as a similar phenotype was observed in B1RB2R-deficient mice. Whether HK also contributes to colitis pathogenesis through other mechanisms (such as enhancement of endotoxin activity) awaits further investigation.

The mechanism that triggers the pKal-HK pathway and may contribute to colonic inflammation can only be speculated upon. Previous studies have shown that the initial step of KKS activation is mediated by the binding of HK to an activation surface (3, 4), made up of negatively charged molecules, such as nucleic acids, over-sulfated chondroitin sulfate, polyporphosphate, collagen, misfolded protein aggregates, lipopolysaccharides, and glycosaminoglycans (3). Thus, HK not only binds to molecules released from necrotic cells such as nucleic acids and polyporphosphate but also to phosphatidyserine from apoptotic cell membrane. In addition, in the lumen of the inflamed colon, HK may bind to bacteria and exuded subendothelial extracellular matrix proteins, leading to activation of the KKS (41). We recently showed that pKal was activated during reactive arthritis induced by peptidoglycan–polysaccharide, and that the pKal-HK pathway is involved in this process (29).

Normally, approximately 75% of pKal circulates in the plasma and is bound noncovalently to HK at a 1:1 ratio (3). Presumably, binding of HK to negatively charged molecules and/or apoptotic/necrotic cells in the local colonic tissue may enrich the pKal–HK complex at this site. Consequently, pKal can be activated to Kal, which cleaves HK to release bradykinin. Bradykinin is a potent modulator of vascular permeability and vasodilatation, and also a major spasmodogen of the smooth muscle of the gut (19). This could explain why HK is needed for the recruitment of pro-inflammatory neutrophils and monocytes into the inflamed colon (Figure 3). Through its two receptors, B1R and B2R, bradykinin induces inflammatory cytokines including IL-1β (11, 29, 42), and increases the levels of a variety of other pro-inflammatory factors such as nitric oxide, prostaglandins, leukotrienes, platelet-activating factor, and neuropeptides (3, 43). A role for IL-1β has previously been suggested in the development of enterocolitis (44–46). The bradykinin receptors, B1R and B2R, are expressed in intestines of both healthy individuals and patients with IBD, but their expression is significantly increased in intestines from patients with active IBD (16). Presumably, once bradykinin is generated following activation of the KKS, it mediates plasma exudation, resulting in a supply of KKS proteins at the inflammatory sites. This positive feedback loop may occur at inflammatory sites, possibly explaining the role of bradykinin in the pathogenesis of IBD. We found that whereas simultaneous deficiency in both bradykinin receptors inhibit colitis, previous studies found that B2R deficiency alone is not sufficient to protect from colitis in the DSS model (47). This suggests an involvement of B1R. However, because of the dynamic expression patterns during disease development, the specific role of the two bradykinin receptors in the pathogenesis of IBD is complex, and additional studies are warranted to evaluate their dynamic cooperation and distinct involvement.

The phenotype of pKal-deficient mice in the two colitis models studied here suggests that Kal contributes to the general mechanism of colitis, which is consistent with the observed ameliorative effect of a Kal inhibitor in an IBD model (13). The release of pKal in the intestinal extracellular space resulting from extravasation of blood is correlated with the degree of tissue inflammation (24). Although the major role of Kal is to generate bradykinin, it may also trigger...
Deficiency of high-molecular-weight kininogen or B1RB2R ameliorates TNBS-induced colitis. Four groups of Kng1<sup>+/+</sup> mice and Kng1<sup>-/-</sup> mice (A–C), and four groups of B1RB2R<sup>+/+</sup> mice and B1RB2R<sup>-/-</sup> mice (D–F) were treated with EtOH or TNBS (<i>n</i> = 12). (A,D) Percentage body weight changes were monitored daily. (B,E) Gross appearance of colons (left) and reduction in colon length (right) were examined. (C,F) Representative H&E staining and histopathological scoring of the colons are shown. Statistical significance was determined by one-way analysis of variance (A–E) or Mann–Whitney test (F): *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001.
Figure 14: Deficiency of prekallikrein, but not factor XII (FXII), ameliorates TNBS-induced colitis. Four groups of Klkb1<sup>+/+</sup> mice and Klkb1<sup>−/−</sup> mice (A–C), and four groups of FXII<sup>+/+</sup> mice and FXII<sup>−/−</sup> mice (D–F) were treated with EtOH or TNBS (n = 12). (A, D) Percentage body weight changes were monitored daily. (B, E) Gross appearance of colons (left) and reduction in colon length (right) were examined. (C, F) Representative H&E staining and histopathological scoring of the colons are shown. Statistical significance was determined by one-way analysis of variance: *P < 0.05; **P < 0.01; ***P < 0.001.
other pathways. For example, Kal can regulate cell signaling by cleaving and activating G protein-coupled proteinase-activated receptors, thereby triggering responses such as vasodilatation, intestinal inflammation, increased cytokine production, and increased nociception (48–50). In addition, Kal itself exhibits chemotactic activity and stimulates the release of neutrophil elastase (51). Although pKal and HK are necessary for colitis pathogenesis, as evidenced by the phenotypes of mice lacking these two genes, we find that FXII is not. There are several mechanisms that may trigger FXII-independent pKal activation leading to bradykinin release from HK. On the cell surface, the lysosomal enzyme prolylcarboxypeptidase can activate pKal in an FXII-independent manner (6). Alternatively, in FXII-deficient plasma, depletion of C1 inhibitor auto-activates pKal-HK complex to release bradykinin (8). In addition, Kal can be activated by heat shock protein 90, which is released from endothelial cells (8, 9). However, the mechanism of FXII-independent activation of pKal in the pathogenesis of colitis requires further investigation. Although FXII presumably does not play a role in the models described here, it may still be involved in other cases. Crohn’s disease, UC, celiac disease, irritable bowel syndrome, and food allergies have been associated with mast cell hyperplasia in the mucosa and humoral activity (52, 53). In mouse models of allergic lung inflammation and Trypanosoma cruzi infection, mast cells release cellular contents such as histamine and polyphosphate that activate FXII, linking mast cell degranulation to FXII-dependent bradykinin release (54, 55).

The phenotypes of B1RB2R-deficient mice suggest that bradykinin and/or des(Arg9)-kinin are the downstream effector molecules involved in the immunopathology in the classical models of DSS or TNBS-induced colitis. These potent peptides, once released in the injured/inflamed mucosa, might modulate the function of a wide range of immune cells, such as neutrophils, macrophages, innate lymphoid cells, dendritic cells (DCs), and T cells (16, 19). Macrophages, DCs, and T cells express GPCRs, including B1R, B2R and PARs (56), but little is known about their role in the intestinal mucosa. In addition, these GPCRs are also expressed by epithelial cells, neurons, and endothelium (16). Because innate immunity is intertwined with neuronal networks (57), the released kinins could play a role in neuro-immune interactions driving colitis development. To further unravel the full complexity of the KKS network in mucosal immunity will be a challenge, and conditional knockout mouse models will be necessary for delineation of the specific role of B1R and B2R in different cell types during the development of colitis.

We recently reported that deficiency of HK, but not pKal or FXII, resulted in protection against endotoxin-induced lethality in mice, suggesting that different KKS proteins play distinct roles in host response to endotoxin (22). The different phenotypes of KKS-deficient mice between endotoxin-induced sepsis and DSS/TNBS-induced colitis probably result from distinct function of the KKS in different disease models. It has been reported that DSS and TNBS increase translocation of the colon-associated microbiota from the gut lumen into the mucosa (58–60). These reagents may hence promote microbial translocation and thereby activate innate immunity receptors to initiate inflammation which leads to plasma leakage into the mucosal tissues. There is also a possibility that the resistant phenotype of Kng1−/− mice and the susceptibility of Kng1−/− mice reconstituted with HK may result from the binding of HK to endotoxin displayed by subsets of bacterial pathogens translocated from the gut and subsequent activation of inflammatory cells via the HK/toll-like receptor (TLR4) pathway. Moreover, following such leakage, pKal, BK, des-Arg9-BK and B2/B1R might further amplify/propagate the inflammation. TLR4 and MD2 are indeed upregulated in colonic tissue during DSS-induced inflammation (61), but if HK is also associated with increased levels of endotoxin and enhance this activation awaits further investigation.

In conclusion, we demonstrated a critical role for the pKal–HK pathway in the pathogenesis of colitis in mouse IBD models. In spite of the difference in the activation of the KKS by DSS and TNBS, both reagents may damage the intestinal barrier integrity, and hence similar phenotypes of the KKS-deficient mice were observed in both models. Our finding offer novel insights into the mechanism underlying IBD pathogenesis and may also provide new prognostic and diagnostic parameters for evaluating IBD severity. Moreover, the pathways controlling KKS activation may lead to new therapeutic targets in the treatment of IBD.

**ETHICS STATEMENT**

This study was carried out in accordance with protocols approved by the Institutional Animal Care and Use Committees of Soochow University and Temple University.

**AUTHOR CONTRIBUTIONS**

BW, AY, ZZ, CH, YL, JD, and YW designed and performed the experiments and collected and analyzed data. RC contributed critical reagents and helped with data interpretation. YW conceived the study, supervised the research, analyzed the data, and wrote the manuscript.

**FUNDING**

This work was supported in part by grants from the U.S. National Institute of Health (AR051713, AR057542, and AR063290), National Natural Science Foundation of China (91539122, 81770138, 91739302, 81301534, and 30971491), and Priority Academic Program Development of Jiangsu Higher Education Institutions.

**REFERENCES**

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. *Annu Rev Immunol* (2010) 28:573–621. doi:10.1146/annurev-immunol-030409-101225
2. Antoni S. Involvement of coagulation and hemostasis in inflammatory bowel diseases. *Curr Vasc Pharmacol* (2012) 10:659–69. doi:10.2174/157016112801784495
3. Wu Y. Contact pathway of coagulation and inflammation. *Thromb J* (2015) 13:17. doi:10.1186/s12995-015-0048-y
4. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibroinolitic, antiadhesive, and proinflamatory attributes. *Blood* (1997) 90:3819–43.
5. Feener EP, Zhou Q, Fickweiler W. Role of plasma kallikrein in diabetes and metabolism. *Thromb Haemost* (2013) 110:434–41. doi:10.1160/TH13-02-0179
6. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. *Blood* (2004) 103:4554–61. doi:10.1182/ blood-2003-07-125233

7. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. *J Biol Chem* (2002) 277:17962–9. doi:10.1074/jbc.M106101200

8. Kaplan AP, Joseph K. Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade. *Immunol Allergy Clin North Am* (2017) 37:513–25. doi:10.1016/j.iac.2017.04.001

9. Joseph K, Tholakanukkel BG, Kaplan AP. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. *J Allergy Clin Immunol* (2009) 124:143–9. doi:10.1016/j.jaci.2009.02.006

10. Simão F, Feener EP. The effects of the contact activation system on hemor-}

11. Fan J, Wu Y, Wang L, Rauova L, Hayes VM, Poncz M, et al. The C-terminal}

12. Yang A, Xie Z, Wang B, Colman RW, Dai J, Wu Y. An essential role of high-

13. Keith JC, Sainz IM, Isordia-Salas I, Pixley RA, Leathurby Y, Albert LM,}

14. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA,}

15. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, et al. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. *Dig Dis Sci* (1996) 41:912–20. doi:10.1007/BF02091530

16. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA, et al. Specific inhibition of plasma kallikrein modulates chronic granulo-

17. Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* (2005) 289:G361–6. doi:10.1152/ajpgi.00369.2004

18. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, et al. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. *Dig Dis Sci* (1996) 41:912–20. doi:10.1007/BF02091530

19. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA, et al. Specific inhibition of plasma kallikrein modulates chronic granulo-

20. Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* (2005) 289:G361–6. doi:10.1152/ajpgi.00369.2004

21. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, et al. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. *Dig Dis Sci* (1996) 41:912–20. doi:10.1007/BF02091530

22. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA, et al. Specific inhibition of plasma kallikrein modulates chronic granulo-

23. Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* (2005) 289:G361–6. doi:10.1152/ajpgi.00369.2004

24. Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, et al. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. *Dig Dis Sci* (1996) 41:912–20. doi:10.1007/BF02091530

25. Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner CA, Adam AA, et al. Specific inhibition of plasma kallikrein modulates chronic granulo-

26. Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation}

27. Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F. A new assay for}

28. StÜRZEBECHER J, SVENSDEN L, EICHENBERGER R, MARKWARDT F. A new assay for}

29. Dai J, Agelan A, Yang A, Zuluaga V, Sexton D, Colman RW, et al. A role for}

30. Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F. A new assay for}

31. Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F. A new assay for}

32. Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F. A new assay for}

33. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. *Proc Natl Acad Sci U S A* (2001) 98:13234–54. doi:10.1073/pnas.231473998

34. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate-induced colitis in mice. *Clin Exp Immunol* (1997) 107:353–8. doi:10.1111/j.1365-2499.1997.ce1184.x

35. Itou R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. *Clin Exp Immunol* (2006) 146:330–8. doi:10.1111/j.1365-2349.2006.03214.x

36. Laukootter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babin BA, et al. JAM-A regulates permeability and inflammation in the intestine in vivo. *J Exp Med* (2007) 204:3067–76. doi:10.1084/jem.200701416

37. Kucharzik T, Russo SJ III, Lugerich D, Leonetti A, Davisson R, Kehret M, et al. Acute induction of human IL-8 production by intestinal epithelium triggers neutrophil infiltration without mucosal injury. *Gastroenterology* (2001) 121:1356–72. doi:10.1053/gast.2001.65168

38. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigra-

39. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigra-

40. Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, et al. Inhibition of plasma kallikrein by a highly specific active site blocking inhibitor. *J Biol Chem* (2014) 289:23596–608. doi:10.1074/jbc.M114.596091

41. Stadnicki A, Colman RW. Experimental models of inflammatory bowel disease. *Arch Immunol Ther Exp* (Warsz) (2003) 51:49–55.

42. Xie Z, Dai J, Yang A, Wu Y. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. *Rheumatology (Oxford)* (2014) 53:1301–6. doi:10.1093/rheumatology/keu190

43. Reshef A, Kidon M, Leibovich I. The story of angioedema: from quincke to bradykinin. *Clin Rev Allergy Immunol* (2016) 51:121–39. doi:10.1007/ s12110-016-0553-8

44. Marceau F, Petitclerc E, DeBiasi D, Pradelles P, Poubelle PE. Human interleukin-1 induces a rapid relaxation of the rabbit isolated mesenteric artery. *Br J Pharmacol* (1991) 103:1367–72. doi:10.1111/j.1365-2499.1991.tb07975.x

45. Petitclerc E, Abel S, DeBiasi D, Poubelle PE. Marceau F. Effects of interleukin-1 receptor antagonist on three types of responses to interleukin-1 in rabbit isolated blood vessels. *J Cardiovasc Pharmacol* (1992) 19:821–9.
46. Petticlerc E, Poubelle PE, Marceau F. Rapid protein synthesis and turnover is involved in interleukin-1-induced relaxation of the rabbit isolated mesenteric artery. Analysis of the arachidonate cascade. *J Pharmacol Exp Ther* (1994) 268:1419–25.

47. Lu F, Fernandes SM, Davis AE. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* (2010) 298:G878–83. doi:10.1152/ajpgi.00400.2009

48. Abdallah RT, Keum J-S, El-Shewy HM, Lee M-H, Wang B, Gooz M, et al. Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. *J Biol Chem* (2010) 285:35206–15. doi:10.1074/jbc.M110.171769

49. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. *Br J Pharmacol* (2005) 146:670–8. doi:10.1038/sj.bjp.0706371

50. Ottaiano TF, Andrade SS, de Oliveira C, Silva MCC, Buri MV, Juliano MA, et al. Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP. *Biochimie* (2017) 135:72–81. doi:10.1016/j.biochi.2017.01.010

51. Wachtfoegl YT, Kucich U, James HL, Scott CE, Schapira M, Zimmerman M, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. *Clin Invest* (1983) 72:1672–7. doi:10.1172/JCI111126

52. Bischoff SC. Mast cells in gastrointestinal disorders. *Eur J Pharmacol* (2016) 778:139–45. doi:10.1016/j.ejphar.2016.02.018

53. Conti P, Caraffa A, Ronconi G, Kritas SK, Mastrangelo F, Tettamanti L, et al. Impact of mast cells in mucosal immunity of intestinal inflammation: inhibitory effect of IL-37. *Eur J Pharmacol* (2018) 818:294–9. doi:10.1016/j.ejphar.2017.09.044

54. Sala-Cunill A, Bjørkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. *Allergy Clin Immunol* (2015) 135:1031–43. e6. doi:10.1016/j.jaci.2014.07.057

55. Nascimento CR, Andrade D, Carvalho-Pinto CE, Serra RR, Vellasco L, Brasil G, et al. Mast cell coupling to the kallikrein-kinin system fuels intracardiac parasitism and worsens heart pathology in experimental Chagas disease. *Front Immunol* (2017) 8:840. doi:10.3389/fimmu.2017.00840

56. Zelawski W, Machnik G, Nowaczyk G, Plewka D, Lorenz C, Rosado K, et al. Expression and localisation of kinin receptors in colorectal polyps. *Int Immunopharmacol* (2006) 6:997–1002. doi:10.1016/j.intimp.2006.01.016

57. Gabanyi I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Mucida D. Neuro-immune interactions drive tissue programming in intestinal macrophages. *Cell* (2016) 164:378–91. doi:10.1016/j.cell.2015.12.023

58. Zhao Y, Zhang S, Jiang L, Jiang J, Liu H. Preventive effects of *Schistosoma japonicum* ova on trinitrobenzenesulfonic acid-induced colitis and bacterial translocation in mice. *J Gastroenterol Hepatol* (2009) 24:1775–80. doi:10.1111/j.1440-1746.2009.05986.x

59. Fiorucci S, Distrettu E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria mononuclear cells reactivity and protects against inflammation in a rodent model of colitis. *Digestion* (2002) 66:246–56. doi:10.1159/000068362

60. Panpetch W, Chancharonthana W, Bootdee K, Nilgate S, Finkelman M, Tumwasorn S, et al. *Lactobacillus rhamnosus* L34 attenuates gut translocation induced bacterial sepsis in murine models of leaky gut. *Infect Immun* (2017) 86(1):e700–17. doi:10.1128/IAI.00700–17

61. Ortega-Cava CF, Ishihara S, Rumi MAK, Kawashima K, Ishimura N, Kazumori H, et al. Strategic compartmentalization of toll-like receptor 4 in the mouse gut. *Immunol (2013) 170:3977–85. doi:10.4049/jimmunol.1300397

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Wang, Yang, Zhao, He, Liu, Colman, Dai and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*